Stocks · News reference
Alnylam Highlights Neuroscience Progress At AAIC 2026, Initiating Phase 2 APPlauDS Study Of Mivelsiran In Down Syndrome-Associated Alzheimer's While Completing cAPPricorn-1 Enrollment In CAA
− Initiates Global Phase 2 APPlauDS Study of Mivelsiran in Down Syndrome–Associated Alzheimer’s Disease (DS-AD) −− Announces Completion of Enrollment in the Phase 2 cAPPricorn-1 Study of Mivelsiran in Cerebral Amyloid
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 15, 2026, 7:48 AM
- Checked
- Jul 15, 2026, 7:48 AM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Biotech Is Booming, But These 2 Stocks Missed the Memo
The iShares Biotechnology ETF is trading at new highs and 18 out of its top 20 constituents are green for the year.
Read original at benzingaAlnylam Pharmaceuticals shares are trading higher after BMO Capital initiated coverage on the stock with a Outperform rating and announced a $318 price target.
Read original at benzingaThis Alnylam Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Top analysts change outlook on ALNY, AGMB, BMRN, BEKE, and IONS with ratings and price targets. Check out opinions and coverage on Benzinga.
Read original at benzinga